AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00272961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet once daily for 12 weeks
Study NCT00272961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBC3711
Description: 10 mg tablets once daily for 10 weeks
Study NCT00272961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBC3711
Description: 50 mg tablet once daily for 10 weeks
Study NCT00272961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBC3711
Description: 100 mg tablet once daily for 10 weeks
Study NCT00272961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBC3711
Description: 200 mg tablet once daily for 10 weeks
Study NCT00923494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 ml of ropivacaine 0.5%
Description: Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
Study NCT00923494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30 ml of ropivacaine 0.5%
Description: Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
Study NCT00923494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 ml of ropivacaine 0.5%
Description: Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
Study NCT00796159 — intervention group
Intervention type: DRUG
Intervention: Olmesartan medoxomil
Description: olmesartan medoxomil 20 mg and HCTZ 12.5 mg
Study NCT04405193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: Eligible patients will be randomised to receive N-acetylcysteine or placebo
Study NCT04405193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT01305317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor
Description: Atorvastatin 20mg daily for 6 months
Study NCT01779908 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT01779908 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02496871 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Phone Calls
Description: University of Kansas Weight Management Program - Group Phone calls
Study NCT02496871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media
Description: University of Kansas Weight Management Program - Social Media (Facebook)
Study NCT02334956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain MRI
Study NCT04896359 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 12.5 grams of ascorbic acid
Study NCT04896359 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle
Study NCT03654261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: The intervention is a 1-day Cognitive Behavioural Therapy based workshop.
Study NCT01838083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine new formulation HOE901
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study NCT00481247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, oral, dasatinib 50-140 mg once daily (QD)
Study NCT00481247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Tablets, oral, imatinib 200-800 mg, QD
Study NCT01140035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of continuous insulin infusion for glycemic control in brain dead donors
Description: As per protocol
Study NCT00321854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramipexole
Study NCT05214157 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: active gas aspiration
Description: sucking remaining Co2 from the peritoneal cavity and local anaesthetic application at port sites
Study NCT01070394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDX Treatment
Description: 30 mg, 50mg, or 70 mg. Oral capsule, once a day, for 12 weeks.
Study NCT03125057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemoporfin PDT
Description: Photodynamic therapy is performed using hemoporfin. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.
Study NCT01402583 — intervention group
Intervention type: DRUG
Intervention: PEG IFN/Ribavirin
Description: PEG IFN/Ribavirin
Study NCT01259401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Intervention Program
Description: Sessions focused on: 1) sleep consolidation and sleep schedule optimization, 2) sleep hygiene education, 3) cognitive therapy, and 4) maintenance of sleep improvements and coping with future bouts of insomnia.
Study NCT01259401 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education control
Description: During sessions, participants reviewed two educational brochures that focused on changes in sleep with age and sleep hygiene education.
Study NCT00245622 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tovaxin Autologous T cell vaccine
Description: subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
Study NCT00245622 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
Study NCT02459639 — intervention group
Intervention type: OTHER
Intervention: Anthroposophic integrative care rehabilitation program
Description: The programme for chronic pain at AIC consists of two phases:~1. A three-week in-patient period. During the first three-week in-patient stay, patients meet regularly with a multi-professional team. Usually, each patient receives two of the following therapies 2-4 times per week: art therapy, massage, physiotherapy, eurhythmy and baths. Nursing care is provided twice daily. Moreover, patients are offered to participate in group activities.~2. Two-three day inpatient follow-up and treatment period closure. The second phase of the treatment programme consists of a 2-3 day inpatient stay, 6 months after closure. During this time, physician, nurse and therapist appointments are made according to individual needs. The patients who have been engaged in group activities are gathered in groups.
Study NCT02459639 — intervention group
Intervention type: OTHER
Intervention: Conventional multi-modal care rehabilitation
Description: The standard approach at Linköping University Hospital admits patients for bio-psycho-social assessment, pharmacological treatment and multimodal rehabilitation (main components: education, intense physical exercise, cognitive behavioural therapy and workplace interventions) for a 6 week intensive phase period (75%) followed by 4 weeks (25%). Here a number of professional disciplines collaborate and form a team of professionals focused on individual patient needs The multimodal rehabilitation outpatient program delivered by this team has the following aims: 1) reduce pain and psychological burden, 2) improve work capacity and decrease sick-leave and 3) increase perceived health and quality of life. These general aims are combined with the aims of the patient in a plan of rehabilitation.
Study NCT05826106 — intervention group
Intervention type: PROCEDURE
Intervention: R anastomosis
Description: Modifying the surgical technique of totally laparoscopic Billroth-II reconstruction with Braun anastomosis and to name it as the R anastomosis.
Study NCT02145403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered starting at dose level 1 (20 mg/m2 IV) on day +1, +2, +6 and +7.~Dose escalation will be performed on the day +6 and day +7 doses only in each dose level. Day +1 and day+2 doses will be fixed at 20 mg/m2 IV in all dose levels.
Study NCT02145403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus will be administered at 0.03 mg/kg continuous infusion over 24 hours, starting on day -3 as standard graft-versus-host disease prophylaxis.
Study NCT04354337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Innovations for Preschoolers with Arthritis (SIPA)
Description: The SIPA intervention is interactive and personalized. Every week, parent will receive an email sent automatically through the system with instructions for this week's activity, designed to take about 30 minutes to complete. The SIPA weekly modules will begin with a learning module, then direct participants through goal setting, anticipated barriers, and problem solving. The intervention site will include fillable responses to queries, instructions, and assignments. Tasks for parents and their young children will use multimedia elements to enhance delivery of information, such as links to videos and pictures targeting self-efficacy, motivation, and patient activation. Submissions and progress will be monitored by the study team, who will send email, call or text with reminders (whichever the family prefers) and answer questions as needed, review progress, and help problem solve any technology issues or barriers to implementing skills.
Study NCT00528879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets administered orally as a 2.5-, 5-, or 10-mg dose once daily for up to 102 weeks
Study NCT00528879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dapagliflozin-matching placebo administered as tablets orally once daily for up to 102 weeks
Study NCT00528879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dapagliflozin-matching placebo administered as tablets orally once daily for up to 102 weeks
Study NCT00528879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Open-label metformin administered as ≥1500 mg per day for up to 102 weeks
Study NCT00528879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Open-label metformin administered as ≥1500 mg per day for up to 102 weeks
Study NCT01880099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo compared to 8mg of Galantamine
Study NCT01880099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galantamine 8mg
Description: 8mg of galantamine compared to placebo
Study NCT01880099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galantamine 16mg
Description: 16mg of galantamine compared to placebo
Study NCT02995837 — intervention group
Intervention type: OTHER
Intervention: Sleep Study
Description: Overnight, video-recorded sleep study will be performed in a dedicated pediatric sleep lab. Sleep architecture, apneas and hypopneas, arterial oxygen saturation and end-tidal carbon dioxide tension will be evaluated during the sleep study. Safety measures including arterial oxygen saturation using pulse oximetry, EEG and EKG will be continuously monitored during the study.
Study NCT02995837 — intervention group
Intervention type: OTHER
Intervention: Neurocognitive Testing
Description: Cognitive and behavioral measures including intelligence, attention, working memory, and processing speed will be assessed by a trained psychologist.
Study NCT02995837 — intervention group
Intervention type: OTHER
Intervention: CBF During Wakefulness
Description: Cerebral blood flow (CBF) will be measure using Diffuse optical and correlation spectroscopy (DOS/DCS), a non-significant risk device used to collect data for this study but not being tested as part of the protocol. Light sources and detectors which are embedded in a rubber pad will be attached to the subject's head in order to record right and left hemispheric cerebral blood flow, total hemoglobin concentration and tissue oxygen saturation. Measurements will be continuously recorded during the study and averaged for purposes of statistical analysis. With DOS/DCS in place, ventilatory response to hypercapnia will be determined using the rebreathing technique, a standard clinical test. While CBF is being measured, subjects will wear nose clips and sit comfortably breathing through a mouthpiece while the level of carbon dioxide is adjusted over a 3-4 minute period. Oxygen and carbon dioxide levels will be carefully monitored throughout the testing.
Study NCT02995837 — intervention group
Intervention type: OTHER
Intervention: CBF During Sleep
Description: This is the same as the CBF testing during wakefulness/daytime except that it will be done during a sleep study performed with a continuous positive airway pressure (CPAP) mask not nose clips and a mouthpiece. With DOS/DCS in place, ventilatory response to hypercapnia will be determined using the rebreathing technique. While CBF is being measured, OSAS subjects will receive an individualized positive pressure aimed at treating obstructive sleep apnea and controls will receive a standard pressure. End-tidal carbon dioxide will be measured via a port in the mask. A constant flow of carbon dioxide will be introduced to the circuit, a slowly adjusted until the patient arouses or for a maximum of 3 minutes, whichever occurs first. One trial will be attempted in each sleep stage (slow-wave sleep and rapid-eye-movement) with a minimum of 15 minute of breathing room air between challenges. Oxygen and carbon dioxide levels will be carefully monitored throughout the testing.
Study NCT01073683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laryngoscopy
Description: Treatment of advanced larynx cancer with induction TPF, in order to decide between chemoradiation and laryngeal preservation surgery
Study NCT01073683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere (Docetaxel), Cisplatin, 5FU
Description: Taxotere 75 mg/m2 D1, Cisplatin 75 mg/m2 D1, 5FU 750 mg/m2 D1-4
Study NCT01261325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dose of two equal intakes of placebo in a double-blinded way for the 12-week treatment period
Study NCT01261325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes of Brivaracetam 100 mg/ day in a double-blinded way for the 12-week treatment period
Study NCT01261325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes of Brivaracetam 200 mg/ day in a double-blinded way for the 12-week treatment period.
Study NCT01261325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs with market authorization available per country
Study NCT01261325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antiepileptic drugs with market authorization available per country
Study NCT02877290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive ventilation (NIV)
Study NCT00436527 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metronidazole gel 1%
Description: Applied once to a test site on the right or left cheek (as determined by a randomization design)
Study NCT03980327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic
Description: Lactobacillus probiotic
Study NCT03980327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: medium chain triglyceride oil
Study NCT01213355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule, single dose, oral, 1 day
Study NCT01213355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: injectable subcutaneous formulation, single dose, 1 day
Study NCT01213355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212377
Description: 5 mg, PF-05212377, capsule, single dose, 1 day
Study NCT01213355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212377
Description: 20 mg, capsule PF-05212377, single dose, 1 day
Study NCT01213355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: scopolamine
Description: injectable subcutaneous formulation, single dose, 1 day
Study NCT01213355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212377
Description: 60 mg PF-05212377, capsule, single dose, 1 day
Study NCT01213355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: scopolamine
Description: injectable sub cutaneous formulation, single dose, 1 day
Study NCT01213355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Tablet, 10mg, single dose, 1 day
Study NCT01213355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine
Description: injectable sub cutaneous formulation, single dose, 1 day
Study NCT00894465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Children are randomized to receive oral midazolam .5 mg/kg prior to undergoing VCUG
Study NCT00894465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Children are randomized to receive a placebo prior to undergoing VCUG
Study NCT03056352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Intravenous medication drip
Study NCT03056352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Intravenous medication drip
Study NCT01375010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 2000 mg QD
Study NCT01375010 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An inactive treatment that is intended to provide baseline measurements for the experimental protocol of a clinical trial, in this case, the vitamin D3.
Study NCT01375010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin Supplements
Description: Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).
Study NCT01375010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin Supplements
Description: Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).
Study NCT00637442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reminyl retard
Description: retard tablets once a day WEEK1-4: 8mg; WEEK 5-8: 16mg, WEEK 9-24: 24mg
Study NCT03214458 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal high flow
Description: The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases/
Study NCT01743677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Single dose 100 mg (5 x 20 mg tablets)
Study NCT01743677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose placebo tablets (5 tablets)
Study NCT01743677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Single dose Avelox 400 mg tablet
Study NCT02436135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablets administered orally for 24 weeks
Study NCT02436135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered per standard of care according to package insert
Study NCT02063698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: auranofin
Description: Given PO
Study NCT02063698 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT01750775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo Capsule
Description: placebo Capsule 4 granules t.i.d. by mouth for 8 weeks
Study NCT01441024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: 20 mg per day of DAS181-FO3 for 5 days
Study NCT01441024 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mg per day of Lactose for 5 days
Study NCT02063698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02063698 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02122211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaine supplement
Study NCT01740492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.15mg/kg
Description: 0.15mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.